Chimeric antigen of herpes zoster virus vaccine and application thereof
Through chimeric antigen technology, the gE protein segment and Fc fragment were combined with the adjuvant AS01B, a domestic shingles vaccine was developed, which solved the problems of high cost and low compliance with the existing vaccine and achieved higher quality and higher efficiency. Immune effects.
Patent Information
- Application Number
- CN202411211753.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-17
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-04-17
AI Technical Summary
The existing shingles vaccines rely on international vaccines, which are costly and have low patient compliance, and lack domestic substitutes to reduce costs and improve immunity.
Chimeric antigen technology was designed, and by combining the extracellular 134 and extracellular 539 segments with the Fc fragment, combined with the adjuvant AS01B, the Chinese hamster ovarian cell expression system was developed to develop a higher immunity Original recombinant vaccine.
A higher quality vaccine preparation has been achieved, significantly improved immunity effect, better than existing GSK vaccines, reduced the cost of vaccines and improved patient compliance.
Smart Images

Figure BDA0005020486520000041 
Figure BDA0005020486520000061 
Figure BDA0005020486520000071
Abstract
Description
[0001] This application is a divisional application of the invention patent application with the original application number 2023104058706, invention name “A chimeric antigen for herpes zoster virus vaccine and its application”, and application date April 17, 2023. Technical Field
[0002] The invention belongs to the field of medicine, and in particular relates to a herpes zoster virus vaccine. Background Art
[0003] Herpes zoster is an acute infectious skin disease caused by the reactivation of the latent varicella zoster virus (VZV) in the body. The first infection with VZV in childhood causes chickenpox. After infection, the virus enters the sensory nerve endings of the skin and moves toward the center along the dorsal roots of the spinal cord or the trigeminal ganglion nerve fibers, and exists in the sensory ganglia of the spinal nerves or cranial nerves in a persistent latent form for a long time. When the human body's immunity is low or it is subjected to non-specific stimulation, the virus becomes active again, grows and multiplies, causing inflammation or necrosis of the invaded ganglia, producing neuralgia, and at the same time, the reactivated virus spreads from one or several adjacent ganglia along the corresponding sensory nerve fibers to the skin, causing clustered blisters on the basis of unilaterally distributed erythema. The incidence of herpes zoster in the Asia-Pacific region is about 1%, and the incidence increases with age. The incidence of herpes zoster after the age of 40-50 is more than 5%. About 9% to 34% of patients with herpes zoster will experience postherpetic neuralgia, with a pain rating of more than level 7, which is considered severe pain and seriously affects the patient's quality of life. There is no specific medicine for herpes zoster and postherpetic neuralgia, so vaccination with herpes zoster vaccine is an effective means of preventing herpes zoster. Currently, there are two herpes zoster vaccines on the market worldwide: Zostavax (live attenuated vaccine technology) and Shingrix (recombinant protein vaccine technology).
[0004] Although from a technical level, recombinant technology is superior to live attenuated vaccine technology. Zostavax is a live attenuated vaccine, which was first approved by the FDA in 2006 for the prevention of people aged 60 and above. In 2011, its scope of application was approved to expand to people aged 50 and above. Shingrix is an adjuvanted recombinant protein vaccine containing varicella-zoster virus glycoprotein E and AS01B adjuvant system. Shingrix was approved by the FDA for the prevention of people aged 50 and above in 2017. Shingrix is administered in 2 doses, 2-6 months apart, injected intramuscularly into the deltoid muscle of the upper arm, at a cost of 1,600 yuan per dose, and a total of 3,200 yuan for the full course of vaccination. There is an urgent need for a domestic vaccine to replace foreign vaccines, reduce costs and increase efficiency, and achieve better patient compliance.
[0005] VZV is the smallest herpes virus. Among its numbered glycoproteins, glycoprotein gE (glycoprotein E) is a late protein encoded by ORF68, a type I transmembrane protein, with a total length of 623aa, of which 544aa is the extracellular region, 17aa is the transmembrane region, and 62aa is the intracellular region, which is rich in N- and O-glycosylation sites. VZV structural protein gE can be expressed in large quantities in virus-infected cells and plays an important role in virus transmission. It is also one of the main antigens that induce host humoral immunity and cellular immunity. Studies have shown that Western blotting and ELISA detection methods have found that the extracellular 1-135 segment of the gE protein is the main antigenic active region, and the 56-75, 86-105 and 116-135 segments are recognized by the sera of patients with varicella and herpes. This result suggests that these three segments are the most important antigenic epitopes (WJ Fowler, M Garcia-Valcarcel, MS Hill-Perkins, G Murphy, DR Harper, DJ Jeffries, NR Burns, S E Adams, AJ Kingsman, GT Layton. Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zostervirus. Virology. 1995 Dec 20; 214(2): 531-40). Summary of the invention
[0006] Through research, the present invention has found that combining the extracellular 134 segment and the extracellular 539 segment of the gE protein has a particularly good effect, so chimeras of different combinations are designed. The antigen technology route adopts the Chinese hamster ovary cell (CHO) expression system. After being matched with an adjuvant, a vaccine with better immunogenicity is obtained, which provides a guarantee for independent exploration and development of subunit recombinant vaccines with better immunogenicity, and helps to get rid of the dependence on international herpes vaccines.
[0007] The present invention first provides a chimeric antigen for preparing a herpes zoster virus vaccine, which is composed of a gE protein extracellular 539 segment and an Fc fragment connected in series;
[0008] or it may be composed of two tandem gE protein extracellular 539 segments and an Fc fragment;
[0009] Or it is composed of the gE protein extracellular segment 539 and extracellular segment 134 and the Fc fragment in series;
[0010] Or it is composed of the gE protein extracellular segment 134 and extracellular segment 539 and the Fc fragment in series;
[0011] The amino acid sequence of the extracellular 134 segment of the gE protein is shown in SEQ ID NO: 1, and the amino acid sequence of the extracellular 539 segment of the gE protein is shown in SEQ ID NO: 15. Preferably, the Fc fragment is derived from a human IgG Fc fragment; more specifically, its amino acid sequence is shown in SEQ ID NO: 16.
[0012] Preferably, the chimeric antigen for preparing a herpes zoster virus vaccine has an amino acid sequence as shown in SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: 13.
[0013] The present invention provides the nucleic acid encoding the chimeric antigen for preparing a herpes zoster virus vaccine, preferably, the nucleotide sequence thereof is shown in SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12 or SEQ ID NO: 14.
[0014] The present invention provides a recombinant expression vector and a recombinant host cell containing the nucleic acid.
[0015] The present invention provides application of the chimeric antigen for preparing herpes zoster virus vaccine in preparing herpes zoster virus vaccine.
[0016] The present invention further provides a herpes zoster virus vaccine, including an immunogenic vaccine obtained by immunizing an animal with the composition of the chimeric antigen and an adjuvant.
[0017] More specifically, the adjuvant is AS01B, and the ratio of adjuvant to antigen is 1:1.
[0018] In a specific embodiment, the animal is a mouse.
[0019] In a preferred embodiment, the immunization dose is: 1 μg, 2 μg, 5 μg per mouse, and the volume is 100 μl per mouse. The immunization procedure is to use a corresponding dose for boosting immunization after one immunization and two weeks later.
[0020] The chimeric antigen constructed by the present invention can obtain higher quality protein, better immune effect, and is superior to the GSK vaccine. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 , N134-Fc HIC chromatography. That is, the gel run diagram of the construction method of FA02 in the table.
[0022] Figure 2, N134-N134-Fc HIC chromatography. That is, the gel run diagram of the construction method of FA03 in the table.
[0023] Figure 3 、N134_Q540_Fc HIC chromatography. That is, the gel run diagram of the construction method of FA04 in the table.
[0024] Figure 4 , Q540-N134-Fc HIC chromatography. That is, the gel run diagram of the construction method of FA05 in the table.
[0025] Figure 5 、Q540_Q540_Fc HIC chromatography. That is, the gel run diagram of the construction method of FA06 in the table.
[0026] Figure 6 , Q540_Fc HIC chromatography. That is, the gel run diagram of the construction method of FA07 in the table. DETAILED DESCRIPTION
[0027] Example 1. Construction of 7 plasmids
[0028] Plasmids, cells and experimental animals:
[0029] pcDNA3.1-VZV-gEx / y (x is the length of extracellular amino acids of different lengths, y is the Fc mammalian system codon optimization sequence). HEK293 cells were purchased from Shanghai Duoning Biotechnology Co., Ltd. BALB / c female mice (6 weeks old) were purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd. and were raised in the company's SPF animal room in accordance with the "Regulations on the Protection of Experimental Animals". The construction methods of the 7 plasmids are as follows: Example 1, in which the sequence of 1-134 amino acids at the N terminal is shown in Sequence 1. The optimized base sequence is shown in Sequence 2. The optimized nucleotide sequence of 1-134 amino acids was concatenated with the FC optimized sequence and cloned into the pcDNA3.1 vector. The above sequence synthesis was completed by Beijing Liuhe BGI Gene Technology Co., Ltd. The Fc fragment can be selected from the immunoglobulin Fc fragment of human, mouse, rabbit, cow, goat, pig, mouse, rabbit, hamster, rat, or guinea pig; the immunoglobulin Fc fragment is preferably the Fc fragment of IgG, IgA, IgD, IgE or IgM; more preferably, it is selected from IgG1 Fc fragment, IgG2 Fc fragment, IgG3 Fc fragment, or IgG4 Fc fragment; in the present invention, the immunoglobulin Fc fragment is a human IgG Fc fragment. Other schemes are similar to scheme 01, and the relevant sequences are shown in the sequence table. The construction modes of different schemes are as follows:
[0030]
[0031] Example 2. Cell transfection
[0032] One day before transfection, use Transpro CD 01 medium at a rate of 1.0×10 6 The cell density on the day of transfection was 1.5-2.0×10 6 cells / mL, and transfection can be performed when the cell viability is higher than 95%; in the 80ml culture system, first add 80μg of plasmid to 2.4ml PBS solution and mix well, marked as liquid A, then add 320μl of PEI to 2.4ml PBS and mix well, after standing for 5 minutes, add liquid A and liquid B together, mix well and let stand for 15 minutes, then add the mixture dropwise to the 80ml culture system shake bottle and culture in a carbon dioxide incubator. 24 after transfection, add feed to the 80mL system: 160μl VPA, 200μl, dextran sulfate, 2.4ml DN feed 2, 240μl, DN feed B2. On the second day after transfection, add 0.8 ml 300 g / l glucose and 1.6 mL 200 mM / L glutamine; on the third day after transfection, add 2.4 ml DNfeed2, 240 μl, DN feed B2; on the fourth day after transfection, add 0.8 ml 300 g / l glucose and 1.6 mL 200 mM / L glutamine; on the fifth day after transfection, take samples and count, harvest the supernatant by centrifugation for purification.
[0033] Example 3. Protein Purification VZVgE PA Affinity Chromatography
[0034] The supernatant of the VZVgE plasmid transiently transfected cells was filtered through 0.8μm and 0.45μm filter membranes, and 80μl was sampled for electrophoresis detection.
[0035] (1) Pretreatment: rinse with 1 M NaOH for at least 3 CV, then rinse with purified water for at least 10 CV, flow rate 5-10 ml / min;
[0036] (2) Equilibration: Elute with binding buffer for 10 CVs to fully equilibrate until the baseline is stable, with a flow rate of 5-10 ml / min;
[0037] (3) Sampling: About 76 ml of the filtered cell supernatant sample is loaded, flow rate: 2.5 ml / min, pressure limit: ≤0.3 MPa; collect the flow-through sample at the end of loading, and take 80 μl for testing;
[0038] (4) Elution: After loading, the flow rate was increased to 5 ml / min, and the binding buffer was used to elute for at least 6 CV until the UV baseline was stable;
[0039] (5) Elution: Use 100% B Buffer for elution at a flow rate of 2.5 ml / min. Collect samples in different tubes according to the UV absorption peak UV280. Collect one tube for each elution gradient.
[0040] (6) Regeneration: First rinse with 1 M NaOH for at least 3 CV, then rinse with purified water for at least 10 CV.
[0041] Example 4. Protein Purification VZVgEHIC Chromatography
[0042] Configuration HICBufferA: 0.02M PB, 1.2 / 1.8M (NH4)2SO4, pH7.8 / 8.0, HICBuffer B: 0.02M PB, Ph7.8, HICBufferC: 0.02M PB, 1.8 / 2.0M (NH4)2SO4, pH7.8 / 8.0
[0043] Take 10 ml of the VZVgE QFF anion exchange chromatography elution sample from the previous step, add 20 ml of HIC Buffer C to make the ammonium sulfate concentration close to 1.2 / 1.8 M, and the final volume is 30 ml.
[0044] Chromatographic column: ToyoScreen Butyl-650M, column volume CV: 5ml, flow rate 1-5ml / min, pressure limit: ≤0.3MPa
[0045] (1) Pretreatment: Wash the column with 2-5 column volumes of salt-free elution buffer (HIC Buffer B);
[0046] (2) Equilibration: Equilibrate the column with 5-10 column volumes of starting buffer (HIC Buffer A), or until the UV absorbance returns to the baseline conductivity.
[0047] (3) Sample loading: dilute the VZVgE QFF sample to about 30 ml, flow rate: 2 ml / min; collect the sample flow-through and take 80 μl of it for testing;
[0048] (4) Elution: After loading, equilibrate the column with 5-10 column volumes of starting buffer or until the UV absorbance returns to the baseline conductivity and collect the elution sample;
[0049] (5) Elution: Gradient elution, using 60%, 75%, 90% and 100% B Buffer respectively, with an elution flow rate of 2.5 ml / min. 280 The target protein was collected by elution at 90% and 100%.
[0050] (6) Washing: Use 2-5 column volumes of salt-free eluent (HIC Buffer B) to wash away any hydrophobic substances bound to the column;
[0051] (7) Equilibrate the column with 5-10 column volumes of starting buffer (HIC Buffer A) or until the UV absorbance returns to baseline and the conductivity stabilizes.
[0052] Example 5. SDS-PAGE electrophoresis and Coomassie Brilliant Blue staining
[0053] Prepare the collected HIC chromatography samples, take 80 μl of each sample, add 20 μl of 5× protein loading buffer, mix well, boil in boiling water for 5 min, and immediately put in an ice bath, store at -20°C for later use. Load the sample for SDS-PAGE electrophoresis detection.
[0054] Chromatography results are shown in Figures 1 to 6 , it can be seen that they are effectively expressed. It can be seen from the figure that the molecular weight of the expressed protein is greater than the theoretical molecular weight of its unglycosylated monomer, that is, the protein is effectively glycosylated and can effectively function. And after fusion with FC, the purification steps are reduced.
[0055] Example 6. Primary immunization of mice
[0056] Five female BALB / c mice aged 6-8 weeks were selected and injected intramuscularly with AS01B adjuvant. The antigen dose was 5μg / 2μg / 1ug and the volume was 100μl / mouse. The corresponding dose was used for booster immunization every 2 weeks. Before each immunization, the mouse serum was collected, placed in a 37℃ constant temperature incubator for 30 minutes, and centrifuged at 13000g for 10 minutes. The serum was collected and the antibody titer of serum gE was measured. The results are shown in the following table.
[0057] Table 1. Neutralizing antibody titer determination results
[0058]
[0059]
[0060] As can be seen from the table, the effects (immune effect and neutralizing antibody titer) of N134-N540-FC or N540-N134-FC or N540-FC are all better than those of GSK vaccine. The immune effect of scheme 03-06 is on the order of hundreds of thousands, while the immune effect of GSK vaccine is on the order of ten thousand.
Claims
1. A chimeric antigen for preparing a herpes zoster virus vaccine, which is composed of a series connection of the extracellular segment 539 and the extracellular segment 134 of the gE protein and an Fc fragment; or a series connection of the extracellular segment 134 and the extracellular segment 539 of the gE protein and an Fc fragment; in, The amino acid sequence of the extracellular 134 segment of the gE protein is shown in SEQ ID NO: 1, and the amino acid sequence of the extracellular 539 segment of the gE protein is shown in SEQ ID NO:
15.
2. The chimeric antigen for preparing a herpes zoster virus vaccine according to claim 1, characterized in that: The Fc fragment is derived from human IgG Fc fragment, more specifically, its amino acid sequence is shown in SEQ ID NO:
16.
3. The chimeric antigen for preparing a herpes zoster virus vaccine according to claim 1, characterized in that: The amino acid sequence thereof is shown in SEQ ID NO:7 or SEQ ID NO:
9.
4. A nucleic acid encoding a chimeric antigen for preparing a herpes zoster virus vaccine as claimed in any one of claims 1 to 3.
5. The encoding nucleic acid according to claim 4, characterized in that The nucleotide sequences thereof are shown in SEQ ID NO: 8 or SEQ ID NO: 10, respectively.
6. A recombinant expression vector containing the nucleic acid according to claim 4 or 5, and a recombinant host cell.
7. Use of the chimeric antigen for preparing a herpes zoster virus vaccine according to any one of claims 1 to 3 in preparing a herpes zoster virus vaccine.
8. A herpes zoster virus vaccine, characterized in that: The invention comprises an immunogenic vaccine obtained by immunizing an animal with a composition of the chimeric antigen according to any one of claims 1 to 3 and an adjuvant.
9. The herpes zoster virus vaccine according to claim 8, characterized in that The adjuvant is AS01B, and the dosage ratio of the adjuvant to the antigen is 1:
1.
10. The herpes zoster virus vaccine according to claim 8 or 9, characterized in that The animal is a mouse.
Citation Information
Patent Citations
VZV recombinant gE-flagellin fusion protein as well as preparation method and application thereof
CN108727503A
Herpes zoster virus vaccine, and preparation method and applications thereof
CN109602901A
Varicella-zoster virus r-gE fusion protein, recombinant varicella-zoster vaccine and preparation method and application of varicella-zoster virus r-gE fusion protein and recombinant varicella-zoster vaccine
CN113683704A
Two recombinant adenoviruses for expressing gE protein of varicella-zoster virus and application
CN114163503A
Varicella zoster virus fusion protein and immunogenic composition comprising same
CN115210249A
